FierceBiotech 18. Feb. 2026 Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
FierceBiotech 17. Feb. 2026 Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
FierceBiotech 17. Feb. 2026 Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data
FierceBiotech 17. Feb. 2026 Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
FierceBiotech 17. Feb. 2026 Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
FierceBiotech 17. Feb. 2026 Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
FierceBiotech 16. Feb. 2026 Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook
FierceBiotech 14. Feb. 2026 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
FierceBiotech 13. Feb. 2026 With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
FierceBiotech 13. Feb. 2026 FDA clears Encora Therapeutics’ wearable wrist device for essential tremor
FierceBiotech 13. Feb. 2026 After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
FierceBiotech 13. Feb. 2026 Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site